CLEVELAND, Jan. 18, 2018 /PRNewswire/ -- The Harrington Discovery Institute at University Hospitals in Cleveland, Ohio, today announced the 2018 Harrington Scholar-Innovator Award recipients. The awards support breakthrough discoveries in diverse research areas including cancer, diabetes, osteoporosis, and addiction.

The Harrington Discovery Institute – part of The Harrington Project for Discovery & Development – fulfills an unmet need in academic medicine: to advance early breakthroughs into the clinical realm. Award recipients are selected for the promise of their research to advance standards of care in medicine, regardless of their institution affiliation.

In addition to financial support awarded to the winners, the Harrington Discovery Institute provides guidance in all aspects of drug discovery from its Innovation Support Center. This is a team of pharmaceutical industry experts who oversee the therapeutic development of Scholar programs. While working with the Harrington Discovery Institute, physician-scientists (and their institutions) retain the intellectual property for their work.

"This extraordinary group of physician-scientists constitutes our sixth class of Harrington Scholar-Innovators. We selected these projects from a highly competitive pool of applications based on their potential to advance from discoveries into medicines that will improve human health," said Jonathan Stamler, MD, President of the Harrington Discovery Institute.

The selected scholars have access to several rounds of capital (up to a total of $700,000) through their affiliation with the Harrington Discovery Institute to support the transition of their work into the private sector. Scholars are then free to approach investors of their choice to underwrite the commercialization of their work. They also have facilitated access to BioMotiv, the mission-aligned development company that is part of The Harrington Project. However, there are no obligations on either side.

"We hear from our scholars that the tailored guidance they receive throughout the program and the connection to a for-profit accelerator are vital to success," added Dr. Stamler. "We know that our model works, and we are pleased to see the results, which to date include launching twenty companies, assisting five programs in entering the clinic, and licensing five technologies to big pharma."

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her
physician.